PATENT CLAIM ANALYSIS

Application Number: 15990935
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "263210"]

Abstract:
The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients for whom metformin therapy is inappropriate due to intolerability or contraindication against metformin.

Claim (Index 14):
The method according to  claim 1 , wherein 3-{(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl}thiazolidine, or a pharmaceutically acceptable salt thereof, is administered in combination with one or more further active substances selected from repaglinide, pioglitazone, and insulin and insulin analogues.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 93.0
- Lexical Diversity: 1.14286
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13057295', '14294630', '15287228', '13143370', '11916356']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7701576492058874
- 35 USC 102 Novelty (BERT): 0.5816793986150758
- Combined Prediction Score: 0.7513098241468062
- Mean Citation Score: 377.57612
- Max Citation Score: 507.50964000000016
- Similarity Product: 401.2728172231365

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test